More medical device companies are being started around relatively focused product plays attractive to both the public markets and big-company acquirors. The most important coming change in surgery, the coupling of less invasive diagnostics and surgery. A conversation with surgeon and device entrepreneur Tom Fogarty on what’s changed over his 30 years of starting up medical device companies.
by Roger Longman
Few people in the early 1990s thought that medical device start-ups would become a hot investment area anytime soon. The...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.
Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.
Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.
Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
It’s no secret that Marty Makary and Robert F. Kennedy Jr. have a different take on user fees, with Makary viewing them as a funding necessity and Kennedy as a corrupting influence. But will they find a way to strike a balance during the next MDUFA reauthorization talks so each can claim victory?
Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.
